tbuckley/cabot-search huggingface dataset:
DIENCEPHALIC EPILEPSY AND THE DIENCEPHALIC SYNDROME
Authors: H MANDELBAUM, S D SPATT, L E FIERER
Journal: Annals of Internal Medicine (1951)

Article1 April 1951DIENCEPHALIC EPILEPSY AND THE DIENCEPHALIC SYNDROMEHARRY MANDELBAUM, M.D., F.A.C.P., SAMUEL DAVID SPATT, M.D., LEON EGON FIERER, M.D.HARRY MANDELBAUM, M.D., F.A.C.P.Search for more papers by this author, SAMUEL DAVID SPATT, M.D.Search for more papers by this author, LEON EGON FIERER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-34-4-911 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHarvey Cushing,1 in his discussion of diencephalic-hypophyseal symptomatology, stated: "Here in this well-concealed spot, almost to be covered by a thumb nail, lies the very mainspring of primitive existence—vegetative, emotional, reproductive—on which, with more or less success, man has come to superimpose a cortex of inhibitions. The symptoms that arise from disturbances of this ancestral apparatus are beginning to stand out in their true significance. . . ."The diencephalo-hypophyseal mechanism can only be properly interpreted when looked upon as a whole. The active principle of the neurohypophysis is in part excreted into the blood stream and in part into...Bibliography1. Cushing H: The pituitary body, hypothalamus and parasympathetic nervous system, 1932, C. C. Thomas, Publisher, Springfield, Ill. Google Scholar2. PenfieldErickson WTC: Epilepsy and cerebral localization, 1941, C. C. Thomas, Publisher, Springfield, Ill. Google Scholar3. Page IH: A syndrome simulating diencephalic stimulation occurring in patients with essential hypertension, Am. J. M. Sc. 190: 9, 1935. CrossrefGoogle Scholar4. SchroederGoldman HAMI: Test for the presence of the "hypertensive diencephalic syndrome" using histamine, Am. J. Med. 6: 162, 1949. CrossrefMedlineGoogle Scholar5. PageCorcoran IHAC: Arterial hypertension, its diagnosis and treatment, 1945, Year Book Publishers, Chicago. Google Scholar6. GoldenbergSnyderAranow MCHH: New test for hypertension due to circulating epinephrine, J. A. M. A. 135: 971, 1947. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, New York*Received for publication April 23, 1949.From the Hypertension and Nephritis Clinic of the Jewish Hospital of Brooklyn. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLong Reflections on the QT Interval:.Hypertonie und erhöhte KatecholaminausscheidungThalamisch-autonome Herdanf�lle als TraumafolgeHypertension Caused by EncephalitisVegetative Herz- und KreislaufstörungenVegetative Herz- und KreislaufstörungenDiencephalic Autonomic Attacks 1 April 1951Volume 34, Issue 4Page: 911-920KeywordsBloodEmotionsEpilepsyHospitalsHypertensionNephritisRivers ePublished: 1 December 2008 Issue Published: 1 April 1951 PDF downloadLoading ...
675. Combination Therapy of Ad-mda7 and Herceptin Increases Cell Death in Her-2/Neu Positive Breast Cancer Cells
Authors: Sunil Chada, Abner Mhashilkar, Tamra McKenzie, Yanna Liu, Stephen G. Swisher, Kelly Hunt
Journal: Molecular Therapy (2004)

Adenoviral mediated transduction of the tumor suppressor melanoma differentiation-associated gene-7 (Ad-mda7) induces apoptosis in a broad spectrum of cancer cells, but not in normal cells. Transgenic MDA-7 protein expression downregulates β-catenin and PI3K signaling in breast cancer cells. Breast cancers overexpressing Her-2/neu are resistant to conventional chemotherapeutic agents, resulting in significantly lower overall survival rates. Herceptin (Trastuzumab), a monoclonal antibody directed against Her-2/neu, improves the efficacy of chemotherapeutics against Her-2/neu-overexpressing breast cancer cells. In this study, we evaluated the impact of combination therapy of Ad-mda7 and Herceptin on Her-2/neu-positive and negative breast cancer cell lines.
Nutrition in the Clinical Management of Disease
Authors: John W. T. Dickerson, Harry Andre Lee
Journal: Gut (1978)

Nutrition for and during pregnancy childhood inborn errors of metabolism in children marasmus and kwashiorkor nutrition in the elderly obesity - management in the treatment of disease anorexia nervosa diabetes mellitus diet in the management of cardiovascular disease diseases of the alimentary tract disorders of the liver and gall bladder the nutritional management of renal disease anaemias and coagulation disorders of nutritional origin mineral metabolism nutrition and disorders of the nervous system nutrition and cancer food intolerance the interrelationships of nutrition and drugs nutritional aspects of different dietary practices nutrition and alcohol assessment of nutritional status enteral feeds parenteral nutrition.
The HECA-452 epitope is highly expressed on lymph cells derived from human skin
Authors: None Hunger, None Yawalkar, None Braathen, None Brand
Journal: British Journal of Dermatology (1999)

The cutaneous lymphocyte-associated antigen (CLA), recognized by the monoclonal antibody HECA-452, is a cell surface glycoprotein that binds specifically to E-selectin. CLA is present on most T cells at sites of cutaneous immune response and has been shown to be important in lymphocyte homing to the skin. It is expressed only by a minor subset of peripheral T cells and is absent on thymocytes. We have analysed (using a FACScan flow cytometer) the expression of CLA on human lymph cells derived from normal skin, from ultraviolet (UV)-irradiated skin and from allergic contact dermatitis. Whereas in the peripheral blood CLA was expressed on < 20% of CD4 +, CD8 + and CD56 + cells (natural killer cells), > 60% of CD4 +, CD8 + and CD56 + cells isolated from skin-derived lymph expressed CLA. Furthermore, > 90% of CD1a + dendritic lymph cells were positive for CLA. UV irradiation of the skin and induction of an allergic contact dermatitis did not change CLA expression on lymph cells, although lymph flow and cell output increased. These results provide further evidence for an important role of CLA in cell homing to the skin.
Community development, user involvement, and primary health care
Authors: B. Fisher, H. Neve, Z. Heritage
Journal: BMJ (1999)

The new primary care groups (local health groups in Wales) will need to shape services, assess health needs, reduce health inequalities, listen to users' views, and work in partnership with local agencies. This will require a range of skills which few primary health professionals currently have.1 Few fundholders undertook any health needs assessment or involved patients in purchasing,2 and the government has provided little conceptual, managerial, or financial infrastructure for public involvement. Public meetings are the only mechanism for consultation mentioned in the white paper—yet these are an inadequate means of genuinely engaging communities in the health issues that matter to them, particularly for marginalised groups. One solution is for primary care to work with community development projects, which have been tackling these issues for years. Community development recognises the social, economic, and environmental causes of ill health and links user involvement and commissioning to improve health and reduce inequalities. Communities can be geographical—such as particular housing estates—or communities of interest, such as user groups. Trained community development workers bring local people together to:
Panton-Valentine leukocidin positive MRSA in 2003: the Dutch situation
Authors: W J B Wannet, M E Heck, G N Pluister, E Spalburg, M G Van Santen, X W Huijsdans, E Tiemersma, A J de Neeling
Journal: Eurosurveillance (2004)

Analysis of methicillin-resistant Staphylococcus aureus (MRSA) isolates in the Netherlands in 2003 revealed that 8% of the hospital isolates carried the loci for Panton-Valentine leukocidin (PVL). Molecular subtyping showed that most Dutch PVL-MRSA genotypes corresponded to well-documented global epidemic types. The most common PVL-MRSA genotypes were sequence type ST8, ST22, ST30, ST59 and ST80. MRSA with ST8 increased in the Netherlands from 1% in 2002 to 17% in 2003. It is emphasised that PVL-MRSA might not only emerge in the community, but also in the hospital environment.
Madame Cézanne in Blue
Authors: M. Therese Southgate
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Significance of Glycosuria
Authors: James E. Paullin
Journal: Annals of Internal Medicine (1929)

Article1 August 1929The Significance of GlycosuriaJAMES E. PAULLIN, M.D.JAMES E. PAULLIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-3-2-137 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen a reducing substance is found in the urine during the course of a routine physical examination, or a patient states that such a substance has previously been found, two questions immediately present themselves for solution: (1) Is the reducing substance glucose? (2) If it is glucose, what condition is responsible for its presence? Upon a correct solution of these problems depends the future welfare and comfort of the patient. It is the purpose of this paper to discuss briefly some of the procedures which are useful in answering these questions.For several years there has been quite a discussion...References BAISH K: Zeit. f. Physiol. Chem., 1895, 20, 248. Google Scholar2 BENEDICTOSTERBERGNEUWIRTH SREI: Jour. Biol. Chem., 1918, 34, 217; Jour. Biol. Chem., 1923, 55, 769. CrossrefGoogle Scholar3 BLATHERWICKBELLHILLLONG NRMEML: Jour. Biol. Chem., 1925, 66, 801. CrossrefGoogle Scholar4 MALMROS H: Acta Med. Scan., 1928, Supplement 27. Google Scholar5 FOLINBERGLUND OH: Jour. Biol. Chem., 1922, 51, 213. CrossrefGoogle Scholar6 GREENWALDGROSSSAMET IJJ: Jour. Biol. Chem., 1925, 62, 401. CrossrefGoogle Scholar7 SHAFFERHARTMANN PAAF: Jour. Biol. Chem., 1920-21, 45, 365. CrossrefGoogle Scholar8 EAGLE HS: Jour. Biol. Chem., 1926-27, 71, 481. CrossrefGoogle Scholar9 PARSONS E: Boston Med. and Surg. Jour., 1926, 195, p. 660. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Atlanta, Georgia*Medical Department, Emory University.†Read before the American College of Physicians, Boston, April 8, 1929. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1929Volume 3, Issue 2Page: 137-143KeywordsForecastingGlucoseUrine Issue Published: 1 August 1929 PDF downloadLoading ...
Electronic Devices and Applications to Track Physical Activity—Reply
Authors: Meredith A. Case, Kevin G. Volpp, Mitesh S. Patel
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL
Authors: Ho Man Chan, Jacob D. Jaffe, Yan Wang, Jinghui Zhang, Robert Huether, Gregory V. Kryukov, Hyo-eun C. Bhang, Jordan E. Taylor, Min Hu, Nathan P. Englund, Feng Yan, Zhaofu Wang, E Robert McDonald, Lei Wei, Jing Ma, John Easton, Zhengtian Yu, Rosalie deBeaumount, Veronica Gibaja, Kavitha Venkatesan, Robert Schlegel, William R. Sellers, Nicholas Keen, Jun Liu, Giordano Caponigro, Jordi Barretina, Vesselina G. Cooke, Charles Mullighan, Steven A. Carr, James R. Downing, Levi A. Garraway, Frank Stegmeier
Journal: Cancer Research (2014)

Abstract Epigenetic dysregulation is an emerging hallmark of cancers. We developed a high-information-content mass spectrometry approach to profile global histone modifications in human cancers. When applied to 115 lines of the Cancer Cell Line Encyclopedia1, this approach identified distinct molecular chromatin signatures. One signature was characterized by increased H3K36 dimethylation, exhibited by several lines harboring NSD2 translocations. A novel NSD2 p.E1099K variant was identified in non-translocated acute lymphoblastic leukemia (ALL) lines sharing this signature. Ectopic expression of the variant induced a chromatin signature characteristic of NSD2 hyperactivation and promoted transformation. NSD2 knockdown selectively inhibited the proliferation of NSD2-mutant lines and impaired the in vivo growth of an NSD2-mutant ALL xenograft. Sequencing analysis of &amp;gt;1000 pediatric cancer genomes identified the NSD2 p.E1099K mutation in 14% of t(12;21)[ETV6-RUNX1]-containing ALLs. These findings identify NSD2 as a potential therapeutic target for pediatric ALL and provide a general framework for the functional annotation of cancer epigenomes. 1. Barretina,J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012). Citation Format: Ho Man Chan, Jacob D. Jaffe, Yan Wang, Jinghui Zhang, Robert Huether, Gregory V. Kryukov, Hyo-eun C. Bhang, Jordan E. Taylor, Min Hu, Nathan P. Englund, Feng Yan, Zhaofu Wang, E Robert McDonald III, Lei Wei, Jing Ma, John Easton, Zhengtian Yu, Rosalie deBeaumount, Veronica Gibaja, Kavitha Venkatesan, Robert Schlegel, William R. Sellers, Nicholas Keen, Jun Liu, Giordano Caponigro, Jordi Barretina, Vesselina G. Cooke, Charles Mullighan, Steven A. Carr, James R. Downing, Levi A. Garraway, Frank Stegmeier. Global chromatin profiling reveals NSD2 mutation in pediatric ALL. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2930. doi:10.1158/1538-7445.AM2014-2930
Evaluation of the prevalence and prospective clinical impact of the <i>JAK2 V617F</i> mutation in coronary patients
Authors: Axel Muendlein, Klaus Gasser, Elena Kinz, Nicole Stark, Andreas Leiherer, Philipp Rein, Christoph H. Saely, Harald Grallert, Annette Peters, Heinz Drexel, Alois H. Lang
Journal: American Journal of Hematology (2013)

The JAK2 V617F mutation is not only found in the majority of patients with myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), but also has been reported in individuals without overt MPN. A close relation of the JAK2 V617F mutation to atherothrombotic events has been described, at least in patients with MPN. The prevalence of the JAK2 V617F mutation and its clinical impact in coronary patients is unknown. To address this issue, DNA samples from 1,589 subjects undergoing coronary angiography with up to 11 years of follow up were genotyped using allele-specific real-time PCR assays. Prevalence of the JAK2 V617F mutation was 1.32% (n = 21) in coronary patients. Two JAK2 V617F positive patients showed baseline platelet counts indicative for ET and a third patient developed ET during follow up, finally resulting in a percentage of 0.188% of ET cases. This corresponds to an up to fivefold accumulation of ET cases in coronary patients compared with the general population. Our study showed no impact of the JAK2 V617F mutation on future atherothrombotic events or overall survival (HR = 1.04 [0.33-3.27]; P = 0.949 and HR = 0.35 [0.05-2.46]; P = 0.288, respectively). Therefore, our data suggest that JAK2 V617F positive coronary patients are not at increased risk for future atherothrombotic complications. Routine mutation screening in coronary patients is, therefore, not warranted. However, number of ET cases appears to be accumulated in coronary patients. For this reason, we recommend JAK2 V617F testing only in coronary patients showing abnormal blood cell counts for further clarification.
Abstract 18389: Predictors of Post-operative Myocardial Infarction in Patients with Previous Myocardial Infarction Undergoing Major Non-cardiac Surgery: Analysis of 30-Day Follow up Data from the ACS-NSQIP
Authors: Ambarish Pandey, Ena Gupta, Purav Mody, Nilay Kumar, Harsh Golwala, Tania Jain, Akshay Sood
Journal: Circulation (2014)

Aim: We sought to identify predictors of recurrent Myocardial Infarction (MI), in patients with a recent history of MI, after undergoing a major non-cardiac surgery using a large national contemporary population-based cohort.

Methods: American College of Surgeons National Surgical-Quality Improvement Program (ACS-NSQIP; 2006-2011) database was used to evaluate 30 day outcomes in patients undergoing one of the 16 major surgical procedures who had a history of MI within the last 6 months of the procedure. Patients were stratified based on incidence of repeat MI event within 30 days of the procedure and pre-operative demographic, anthropometric and clinical characteristics were compared among the patient groups. Multivariable adjusted logistic regression analysis was used to identify the significant predictors of postoperative MI among these patients.

Results: A total of 1568 patients with an episode of MI within last 6 months (35.8 % women; Mean age = 70 years) undergoing one of the 16 major surgical procedures (73% vascular surgery; 20% Gastrointestinal surgery) were included in the analysis. Overall, 3.7% (n = 57) patients had repeat MI events within 30 days after surgery. Patients with post-operative MI were older (75 vs.69 years; P value :< 0.001), had higher prevalence of DM (47.4% vs 34.5%; P value; 0.04), and were symptomatic with angina (26.3% vs 15.5%; P value; 0.03) within 30 days prior to procedure. On multivariable adjusted logistic regression analysis, age and presence of angina within 30 days prior to surgery were each independently associated with increased risk of postoperative MI [see Table].

Conclusion: Presence of angina in patients with previous MI who are undergoing major non-cardiac surgery is an independent predictor of recurrent post-operative MI. A more careful approach in pre operative evaluation in patients with angina is warranted to improve surgical outcomes.

   ![][1]  [1]: /embed/graphic-1.gif
Abstract 17709: Endothelial Overexpression of LOX-1 Increases Aortic oxLDL Uptake, Induces Endothelial Dysfunction and Plaque Formation in vivo. Role of Oct-1, SIRT-1 and NF{kappa}B
Authors: Alexander Akhmedov, Izabela Rozenberg, Yi Shi, Carola Doerries, Pavani Mocharla, Alexander Breitenstein, Christine Lohmann, Sokrates Stein, Jan Boren, Michael O Kurrer, Felix C Tanner, Ulf Landmesser, Christian M Matter, Thomas F Luescher
Journal: Circulation (2010)
Asymptomatic Papular Eruption in a Teenage Boy
Authors: Samantha Gordon, Jodi J. Speiser, Lily Changchien Uihlein
Journal: JAMA Dermatology (2015)

Ahealthyteenagedboywasseenwithapapulareruptiononthetrunkand legsof3months’ duration. He had initially developed lesions on his legs, which then spread to his neck, chest, and buttocks. This eruption was asymptomatic, and the patient reported no history of vesiculation. His mother noted minimal evolution of the lesions, except for recent flattening of those on the legs. Physical examination showed numerous discrete (1 to 3 mm) smooth brown papules concentrated on the neck, chest, anterior and lateral thighs, and buttocks (Figure 1). Several lesions had a positive Darier sign (Figure 1A). There was no family history of similar lesions. A punch biopsy of a papule on the left thigh was performed, and the specimen was submitted for pathological review. Quiz at jamadermatology.com A B